Bioinformatics validation suggested that TAGLN2 was significantly overexpressed in the lung tissues of PAH patients (P < .05), and its succinylation modification might enhance the pro-PAH effect by altering protein stability and function. The gene discussed is TAGLN2; the disease is pulmonary arterial hypertension.